Suven (SUVENPHAR) | Financial Analysis & Statements
Suven Pharmaceuticals Ltd. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
4.0B
Gross Profit
2.7B
66.67%
Operating Income
467.8M
11.64%
Net Income
387.3M
9.63%
Balance Sheet Metrics
Total Assets
30.3B
Total Liabilities
11.9B
Shareholders Equity
18.4B
Debt to Equity
0.65
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Mar 31, 2025
Annual Income Flow
2025
Suven Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 12.0B | 10.4B | 13.3B | 13.1B | 10.0B |
| Cost of Goods Sold | 3.1B | 4.5B | 5.9B | 5.7B | 4.4B |
| Gross Profit | 8.9B | 5.9B | 7.4B | 7.3B | 5.6B |
| Gross Margin % | 74.5% | 56.7% | 56.0% | 56.2% | 56.2% |
| Operating Expenses | |||||
| Research & Development | - | - | 85.9M | 103.5M | 110.6M |
| Selling, General & Administrative | - | 295.2M | 365.7M | 366.2M | 265.8M |
| Other Operating Expenses | 2.7B | 271.4M | 250.3M | 179.2M | 167.7M |
| Total Operating Expenses | 2.7B | 566.6M | 701.8M | 649.0M | 544.0M |
| Operating Income | 3.0B | 3.5B | 5.3B | 5.4B | 4.1B |
| Operating Margin % | 24.9% | 34.3% | 39.5% | 41.6% | 41.3% |
| Non-Operating Items | |||||
| Interest Income | - | 20.2M | 58.3M | 686.0K | 2.7M |
| Interest Expense | 123.5M | 74.5M | 128.1M | 62.3M | 91.4M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 3.4B | 4.1B | 5.6B | 6.7B | 4.7B |
| Income Tax | 791.5M | 1.1B | 1.5B | 2.1B | 1.1B |
| Effective Tax Rate % | 23.0% | 26.0% | 26.5% | 32.0% | 22.5% |
| Net Income | 2.6B | 3.0B | 4.1B | 4.5B | 3.6B |
| Net Margin % | 22.1% | 29.0% | 30.9% | 34.7% | 36.4% |
| Key Metrics | |||||
| EBITDA | 4.3B | 4.2B | 6.0B | 6.4B | 5.1B |
| EPS (Basic) | ₹10.52 | ₹11.80 | ₹16.16 | ₹17.83 | ₹14.23 |
| EPS (Diluted) | ₹10.45 | ₹11.80 | ₹16.16 | ₹17.83 | ₹14.23 |
| Basic Shares Outstanding | 251682510 | 254564956 | 254564956 | 254565000 | 254564956 |
| Diluted Shares Outstanding | 251682510 | 254564956 | 254564956 | 254565000 | 254564956 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Suven Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 854.0M | 472.3M | 648.0M | 445.6M | 71.8M |
| Short-term Investments | 2.1B | 7.7B | 4.2B | 4.8B | 1.8B |
| Accounts Receivable | 2.8B | 1.3B | 1.1B | 2.4B | 1.0B |
| Inventory | 1.7B | 2.3B | 3.1B | 2.8B | 2.0B |
| Other Current Assets | 1.1B | 1.0K | 3.0K | 14.6M | 153.0K |
| Total Current Assets | 8.9B | 12.6B | 10.1B | 11.3B | 5.6B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 10.0B | 937.1M | 680.8M | 474.1M | 449.7M |
| Goodwill | 13.7B | 1.2B | 1.2B | 22.4M | 25.9M |
| Intangible Assets | 638.9M | 16.7M | 19.3M | 22.4M | 25.9M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 28.2M | -3.0K | -4.0K | -1.0K | -1.0K |
| Total Non-Current Assets | 21.4B | 9.9B | 9.5B | 7.0B | 9.1B |
| Total Assets | 30.3B | 22.5B | 19.7B | 18.3B | 14.7B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 802.1M | 423.6M | 700.9M | 1.1B | 829.3M |
| Short-term Debt | 1.0B | 437.6M | 650.8M | 682.2M | 1.1B |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 70.7M | 65.1M | 21.4M | 21.0M | 22.6M |
| Total Current Liabilities | 3.7B | 1.1B | 1.6B | 2.1B | 2.2B |
| Non-Current Liabilities | |||||
| Long-term Debt | 1.8B | 212.4M | 52.6M | 289.0M | 363.3M |
| Deferred Tax Liabilities | 909.8M | 647.9M | 582.3M | 543.2M | 309.3M |
| Other Non-Current Liabilities | - | 1.0K | - | - | 100.0K |
| Total Non-Current Liabilities | 8.3B | 965.3M | 717.9M | 921.1M | 739.2M |
| Total Liabilities | 11.9B | 2.0B | 2.3B | 3.0B | 2.9B |
| Equity | |||||
| Common Stock | 254.6M | 254.6M | 254.6M | 254.6M | 254.6M |
| Retained Earnings | - | 17.7B | 14.7B | 12.7B | 9.4B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 18.4B | 20.5B | 17.4B | 15.3B | 11.8B |
| Key Metrics | |||||
| Total Debt | 2.8B | 650.0M | 703.4M | 971.3M | 1.4B |
| Working Capital | 5.2B | 11.6B | 8.5B | 9.2B | 3.5B |
Balance Sheet Composition
Suven Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 3.4B | 4.1B | 5.6B | 6.7B | 4.7B |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 149.1M | 19.7M | - | - | - |
| Working Capital Changes | -738.4M | 729.9M | 425.7M | -2.2B | -214.2M |
| Operating Cash Flow | 2.9B | 4.9B | 6.1B | 4.5B | 4.6B |
| Investing Activities | |||||
| Capital Expenditures | -1.6B | -517.9M | -2.9B | -751.9M | -1.1B |
| Acquisitions | -7.3B | - | 0 | 2.4B | - |
| Investment Purchases | -3.5B | -3.1B | -44.0K | -3.0B | -2.0B |
| Investment Sales | 9.8B | 11.1M | 844.6M | 2.4B | - |
| Investing Cash Flow | -2.6B | -3.6B | -2.0B | 1.1B | -3.1B |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | -2.0B | -1.0B | -254.6M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | -18.5M | - | - | - | - |
| Financing Cash Flow | 227.9M | -270.4M | -2.1B | -1.4B | -129.0M |
| Free Cash Flow | 1.3B | 3.1B | 1.7B | 2.5B | 2.7B |
| Net Change in Cash | 622.0M | 949.1M | 2.0B | 4.2B | 1.3B |
Cash Flow Trend
Suven Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
99.01
Forward P/E
57.20
Price to Book
13.88
Price to Sales
39.38
PEG Ratio
-9.13
Profitability Ratios
Profit Margin
26.63%
Operating Margin
31.70%
Return on Equity
14.38%
Return on Assets
8.73%
Financial Health
Current Ratio
2.43
Debt to Equity
1.95
Beta
1.13
Per Share Data
EPS (TTM)
₹10.90
Book Value per Share
₹77.73
Revenue per Share
₹41.18
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SUVENPHAR | 412.9B | 99.01 | 13.88 | 14.38% | 26.63% | 1.95 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Torrent | 1.4T | 61.35 | 16.50 | 25.18% | 17.83% | 33.40 |
| Cipla | 1.1T | 23.20 | 3.20 | 16.85% | 16.26% | 1.42 |
| Mankind Pharma | 946.6B | 53.43 | 6.23 | 13.67% | 12.79% | 53.89 |
Financial data is updated regularly. All figures are in the company's reporting currency.
